RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GUTIERREZ M
Collezione ASL Asti

Items : 4

Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis. in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association / Clin Gastroenterol Hepatol. 2024 Oct;22(10):2062-2074.e11. doi: 10.1016/j.cgh.2024.05.008. Epub 2024

2024
ASL Asti
AOU Città della Salute di Torino
AOU Novara
ASL Biella

Vespasiani-Gentilucci U; Carbone M; Sacco R; Izzi A; Fernandez-Rodriguez C; Cuccorese G; Pozzoni P; Pedone C; Grasso S; Picardi A; Invernizzi P; Vigano R; Rigamonti C; Zolfino T; Saitta C; Terreni N; Russello M; Baiocchi L; Bertino G; Rosina F; Cozzolongo R; Simone L; Alagna G; Galli A; Mussetto A; Pompili M; Marra F; Brunetto M; Ponziani FR; et alii...

PREDICTION OF BIOCHEMICAL RESPONSE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH OBETICHOLIC ACID: DERIVATION AND EXTERNAL VALIDATION OF THE OCA RESPONSE SCORE (ORS) in Hepatology

2023
ASL Asti
ASL Biella

De Vincentis A; Ampuero J; Terracciani F; D'Amato D; Invernizzi P; Morgando A; Vanni E; Viganò M; Alvaro D; Venere R; Lleo A; Colapietro F; Degasperi E; Viganò R; Giannini EG; Labanca S; Feletti V; Mussetto A; Cozzolongo RF; Losito F; Pompili M; Ponziani FR; Niro GA; Cotugno R; Pozzoni P; Chessa L; Cuccorese G; Palitti VP; Russello M; et alii...

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. in Journal for immunotherapy of cancer / J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697.

2022
ASL Asti

Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J;

Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study in Cancer Research

2021
ASL Asti

Lin C-C; Zucali P; Carthon B; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su W-C; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen Y-C; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; De Bono J;